Anti-TET2 polyclonal antibody (DPABH-28305) Knockout Validated

Rabbit anti-Mouse TET2 (aa 1600-1700) polyclonal antibody for ICC/IF, WB, IP


Host Species
Antibody Isotype
Species Reactivity
Synthetic peptide corresponding to Mouse Tet2 aa 1600-1700 conjugated to Keyhole Limpet Haemocyanin (KLH).Database link: Q4JK59


Application Notes
WB: 1/250.
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.


Alternative Names
TET2; tet methylcytosine dioxygenase 2; methylcytosine dioxygenase TET2; tet oncogene 2; tet oncogene family member 2; probable methylcytosine dioxygenase TET2
Entrez Gene ID
UniProt ID

Product Background

Gene summary
TET2 (Tet Methylcytosine Dioxygenase 2) is a Protein Coding gene. Diseases associated with TET2 include myelodysplastic syndrome and refractory anemia. Among its related pathways are Gene Expression and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. GO annotations related to this gene include ferrous iron binding and methylcytosine dioxygenase activity. An important paralog of this gene is TET1. The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene.
Antigen Description
Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Note=TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Note=TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Polycythemia vera (PV) [MIM:263300]: A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. The function about TET2 antigen include metal ion binding; methylcytosine dioxygenase activity; oxidoreductase activity; oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen.


Have you cited DPABH-28305 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling

We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Ficz, G; Branco, MR; et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. NATURE 473:398-U589(2011).
Jawert, F; Hasseus, B; et al. Loss of 5-Hydroxymethylcytosine and TET2 in Oral Squamous Cell Carcinoma. ANTICANCER RESEARCH 33:4325-4328(2013).

Online Inquiry

Phone: *
E-mail Address: *
Service & Products Interested: *
Project Description:
Verification Code: * Please input "diagnostics" as verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket